EGX-A

Last updated
EGX-A
Clinical data
Other namesEGXA
Drug class Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. [1] [2] [3] It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. [3] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. [1] [2] As of January 2024, it is in the preclinical research stage of development. [1] [2]

Contents

See also

References

  1. 1 2 3 "EGX A - AdisInsight". adisinsight.springer.com.
  2. 1 2 3 "Delving into the Latest Updates on EGX-A with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. 1 2 Bowen C, Khan T, Perni R, Aron R, Gibbs A, Shin R, Halberstadt A, Premoli I, Kleine P, Rao S, Short G (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (275–275). doi:10.1038/s41386-023-01756-4. PMC   10729596 . PMID   38040810.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.